PRAX (Praxis Medicines) Forvard P/E multiplikatori

PRAX (Praxis Precision Medicines) - kompaniyaning tovar belgisi

Praxis Precision Medicines (PRAX) kompaniyasining barqarorligi epilepsiya va Parkinson kasalliklari uchun terapiyalarni tijoratlashtirishga asoslangan. Kompaniyaning taxminiy forward P/E ko'rsatkichi bozor kayfiyatini aks ettiradi va joriy daraja 0.00 atrofida shakllangan. Neyromeditsina sohasidagi yuqori nufuz shifokorlarning aniq davolash usullariga bo'lgan ishonchini tasdiqlaydi, biolaboratoriya qoidalariga rioya qilish va raqamlashtirish esa biznesning ekologik ta'sirini minimallashtiradi.

praxismedicines.com - PRAX Narxning kelajakdagi foydaga nisbati (davr: 04.07.2022 - 15.11.2026)

Praxis Precision Medicines, Inc. (PRAX) kompaniyasining tahliliy kesimlari va maʼlumotlar hisoboti

- aksiyalar qiymati va narxlar bo'yicha konsensus prognoz:
- biznesning bozor baholash ko'rsatkichlari:
praxismedicines.com brend mahsuloti

Praxis Precision Medicines (PRAX) epilepsiya davolash vositalari uchun qimmat turadigan tadqiqot va ishlanmalarga (R&D) investitsiya kiritmoqda, bu esa vaqtincha operatsion foyda olish imkoniyatini cheklaydi. Kompaniyaning oldingi P/E koeffitsiyentini tahlil qilishda investor aksiyaning bozor narxini har bir aksiyaga to'g'ri keladigan kutilayotgan foyda bilan nisbatda baholaydi. Ushbu koeffitsient bozorning kelajakdagi mahsulotlar portfelining muvaffaqiyati uchun qo'shimcha to'lov qilishga tayyorligini o'lchaydi. Ushbu ko'rsatkichning pasayishi aksiyaning qadrsizlanganligini yoki daromadlar pasayishi xavflarining ortganligini anglatishi mumkin.

Praxis Precision Medicines raqobatchilari tahlili

Forvard P/E multiplikatori BIIB|NBIX - Prognoz qilingan narx-foyda nisbati|Forvard P/E multiplikatori RGC (Regencell Bioscience Ltd)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Kelajakdagi narxning foydaga nisbati|Supernus Corp - Kelajakdagi narx-foyda multiplikatori|Prognoz qilingan narxning foydaga nisbati CPRX|Denali Therapeutics Inc. (DNLI) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Prognoz qilingan narxning foydaga nisbati HRMY (Harmony Corp)|BHVN - Prognoz qilingan narx-foyda nisbati|Kelajakdagi narxning foydaga nisbati Amylyx Pharmaceuticals, Inc. AMLX|Kelajakdagi narx-foyda multiplikatori TRVI|anavex.com - Forvard P/E multiplikatori|Kelajakdagi narx-foyda multiplikatori CBLL (CeriBell, Inc.)|PRTA: Forvard P/E multiplikatori|Narxning kelajakdagi foydaga nisbati ALEC|ANNX (Annexon Biosciences Inc.) - Forvard P/E multiplikatori|omeros.com - Narxning kutilayotgan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Neurogene (NGNE)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati AC Immune SA|Forvard P/E multiplikatori VYGR (voyagertherapeutics.com)|Forvard P/E multiplikatori Neumora NMRA|Scilex Holding - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati Tevogen Bio Inc.|Alpha Cognition (ACOG) - Kelajakdagi narxning foydaga nisbati|cogrx.com (CGTX) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Inhibikase Therapeutics|Cassava (SAVA) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Assertio Therapeutics (ASRT)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Coya|Vistagen - Prognoz qilingan narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori OVID|Acumen Pharmaceuticals Inc. - Forvard P/E multiplikatori|Prognoz qilingan narx-foyda nisbati CervoMed Inc|ATHE: Forvard P/E multiplikatori|Prognoz qilingan narxning foydaga nisbati Clene Nanomedicine|Kelajakdagi narxning foydaga nisbati PepGen Corp|Jupiter Neurosciences (JUNS) - Kapitalizatsiyaning prognoz qilingan foydaga nisbati|Kelajakdagi narxning foydaga nisbati Relmada Therapeutics, Inc. (RLMD)|ANVS - Prognoz qilingan narx-foyda nisbati|gracetx.com - Prognoz qilingan narxning foydaga nisbati|AIFF: Narxning kelajakdagi foydaga nisbati|Klotho Neurosciences - Forvard P/E multiplikatori|NRSN (NeuroSense Therapeutics Ltd.) - Narxning kelajakdagi foydaga nisbati|Reviva Pharmaceuticals (RVPH) - Kelajakdagi narxning foydaga nisbati|MTVA (MetaVia Inc.) - Kelajakdagi narxning foydaga nisbati|Kelajakdagi narxning foydaga nisbati NeurAxis, Inc|Kelajakdagi narxning foydaga nisbati HSDT|Forvard P/E multiplikatori PASG|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Prognoz qilingan narxning foydaga nisbati|Forvard P/E multiplikatori Athira ATHA|Addex Therapeutics - Forvard P/E multiplikatori|ALZN - Forvard P/E multiplikatori|Cyclerion (CYCN) - Kelajakdagi narxning foydaga nisbati|Protagenic (PTIX) - Forvard P/E multiplikatori|Kelajakdagi narxning foydaga nisbati Pasithea|Narxning kelajakdagi foydaga nisbati CRGT (Cortigent)|Kelajakdagi narxning foydaga nisbati Avenue Therapeutics (ATXI)|BCLI - Prognoz qilingan narx-foyda nisbati|Forvard P/E multiplikatori CARA (Cara Therapeutics Inc)|CHRO - Prognoz qilingan narxning foydaga nisbati|ELYM: Prognoz qilingan narxning foydaga nisbati|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Kelajakdagi narxning foydaga nisbati|Marinus - Kelajakdagi narx-foyda multiplikatori|Kelajakdagi narxning foydaga nisbati NKGen Biotech Inc|NRBO: Kelajakdagi narx-foyda multiplikatori|Prognoz qilingan narxning foydaga nisbati SAGE (Sage Therapeutics, Inc.)|Kapitalizatsiyaning prognoz qilingan foydaga nisbati Neurotrope|Kelajakdagi narxning foydaga nisbati Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Prognoz qilingan narx-foyda nisbati|WENA: Prognoz qilingan narxning foydaga nisbati|Kelajakdagi narx-foyda multiplikatori CERE (Cerevel Therapeutics)